Thermo Fisher partners with HealthVerity for enterprise access to real-world claims dataset
Thermo Fisher's PPD clinical research business will gain enterprise-level access to HealthVerity's taXOnomy claims dataset (270M+ de-identified US patient records) plus 70+ linked sources, to support trial feasibility, patient recruitment and real-world evidence work for biopharma sponsors.
Where the rake sits
HealthVerity keeps the enterprise licence fee and owns the rake: it did the identity resolution (HVID), curated taXOnomy's open and closed claims, and linked 70+ sources into the dataset PPD came for. Whatever incremental revenue PPD earns from faster trial startup and RWE deliverables to biopharma clients stays with Thermo Fisher; without a performance mechanic in public view, HealthVerity cannot see what the substrate was worth downstream.
What happened
- Thermo Fisher's PPD gains enterprise-level access to HealthVerity's taXOnomy claims dataset covering 270M+ de-identified US patient records.
- Access extends to 70+ curated sources including EMR, lab and specialty datasets.
- The collaboration is expected to boost RWE and HEOR capabilities across PPD CorEvitas Clinical Registries and PPD Evidera solutions.
- Krishna Cheriath, VP Head of Clinical Research, Digital and AI at Thermo Fisher Biopharma Services, framed the deal around AI-enabled analytics on linked healthcare data.
Who is involved
Thermo Fisher Scientific is an American life science and clinical research company.
2025 annual revenue US$44.556B
HealthVerity partners with pharma, payers and government agencies to synchronize Identity, Privacy, Governance and Exchange.
The reading
HealthVerity does the data-side enrichment: identity resolution (HVID), curation of taXOnomy's open and closed claims, and linkage across 70+ sources into one HIPAA-certified dataset. PPD then applies this inside its own trial-feasibility and RWE workflows.
The payer is Thermo Fisher's PPD. Its decision is which sites and patient cohorts to target for clinical-trial feasibility and which real-world evidence studies to run for its pharma clients; the 270M+ patient claims footprint plus 70+ linked sources feed that specific operational call.
What crosses is enterprise access to the de-identified dataset for PPD's research use; the underlying patient identities, HealthVerity's HVID technology, and the supplier relationships behind taXOnomy do not. In-place access to the dataset is still a sell per the author's Tempus rulings.
Not determinable; licence economics are not disclosed, and whether PPD extracts more value than the fee reflects cannot be read from the announcement.
Why it matters
HealthVerity sold the input that lets PPD win and run trials faster for biopharma sponsors. It sold it as an enterprise licence, while PPD's downstream revenue from CorEvitas and Evidera engagements grows with every sponsor it serves. The licence was announced in April on a 270M-patient footprint; a month later HealthVerity bought Symphony Health and its claims and prescription data, and nothing in public view says whether the same enterprise terms now buy the larger asset. No usage mechanic reveals what PPD actually extracts. That is where specification debt accrues.
The argument this deal tests: The rake is decided before the negotiation begins
Related deals
- TriNetX licenses access to data on about 300 million patients to Regeneron for drug discovery2026-04-02
- Tempus expands multi-year Merck collaboration giving Merck access to de-identified multimodal data and Lens platform2026-03-03
- Neuberger and KKR agree significant minority stake in health-data platform Datavant alongside New Mountain2026-09-15
Sources
- digitalhealthnews.com — primary
- google.com — party background
- drugdiscoverytrends.com — party background
- tracxn.com — party background
- healthverity.com — party background
Announced 2026-08-14